CARL ZEISS MEDITEC AG - BR (AFX.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:AFX - DE0005313704 - Common Stock
39.44 EUR
-0.22 (-0.55%)
We assign a fundamental rating of 5 out of 10 to AFX. AFX was compared to 68 industry peers in the Health Care Equipment & Supplies industry. AFX has an excellent financial health rating, but there are some minor concerns on its profitability. AFX has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- AFX had positive earnings in the past year.
- AFX had a positive operating cash flow in the past year.
- Each year in the past 5 years AFX has been profitable.
- Each year in the past 5 years AFX had a positive operating cash flow.
1.2 Ratios
- With a decent Return On Assets value of 4.15%, AFX is doing good in the industry, outperforming 60.29% of the companies in the same industry.
- AFX has a Return On Equity (6.67%) which is in line with its industry peers.
- Looking at the Return On Invested Capital, with a value of 5.79%, AFX is in line with its industry, outperforming 51.47% of the companies in the same industry.
- AFX had an Average Return On Invested Capital over the past 3 years of 7.11%. This is below the industry average of 9.73%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROIC | 5.79% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
1.3 Margins
- AFX has a Profit Margin (6.34%) which is comparable to the rest of the industry.
- AFX's Profit Margin has declined in the last couple of years.
- The Operating Margin of AFX (10.03%) is comparable to the rest of the industry.
- AFX's Operating Margin has declined in the last couple of years.
- The Gross Margin of AFX (52.76%) is comparable to the rest of the industry.
- AFX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% |
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AFX is still creating some value.
- The number of shares outstanding for AFX remains at a similar level compared to 1 year ago.
- The number of shares outstanding for AFX has been reduced compared to 5 years ago.
- The debt/assets ratio for AFX has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 3.42 indicates that AFX is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 3.42, AFX is in the better half of the industry, outperforming 67.65% of the companies in the same industry.
- The Debt to FCF ratio of AFX is 4.41, which is a neutral value as it means it would take AFX, 4.41 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 4.41, AFX is in line with its industry, outperforming 55.88% of the companies in the same industry.
- AFX has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.27, AFX is in the better half of the industry, outperforming 61.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 3.42 |
ROIC/WACC0.86
WACC6.71%
2.3 Liquidity
- A Current Ratio of 2.35 indicates that AFX has no problem at all paying its short term obligations.
- The Current ratio of AFX (2.35) is better than 69.12% of its industry peers.
- A Quick Ratio of 1.44 indicates that AFX should not have too much problems paying its short term obligations.
- AFX has a Quick ratio of 1.44. This is in the better half of the industry: AFX outperforms 72.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
- The earnings per share for AFX have decreased strongly by -19.90% in the last year.
- Measured over the past 5 years, AFX shows a small growth in Earnings Per Share. The EPS has been growing by 3.28% on average per year.
- The Revenue has been growing slightly by 7.82% in the past year.
- The Revenue has been growing by 10.78% on average over the past years. This is quite good.
EPS 1Y (TTM)-19.9%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-14.49%
Revenue 1Y (TTM)7.82%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%8.27%
3.2 Future
- The Earnings Per Share is expected to grow by 19.64% on average over the next years. This is quite good.
- Based on estimates for the next years, AFX will show a small growth in Revenue. The Revenue will grow by 6.21% on average per year.
EPS Next Y24.48%
EPS Next 2Y22.06%
EPS Next 3Y22.65%
EPS Next 5Y19.64%
Revenue Next Year4.23%
Revenue Next 2Y5.18%
Revenue Next 3Y5.72%
Revenue Next 5Y6.21%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 24.50, the valuation of AFX can be described as rather expensive.
- Compared to the rest of the industry, the Price/Earnings ratio of AFX indicates a somewhat cheap valuation: AFX is cheaper than 72.06% of the companies listed in the same industry.
- AFX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.47.
- With a Price/Forward Earnings ratio of 19.68, AFX is valued on the expensive side.
- Based on the Price/Forward Earnings ratio, AFX is valued a bit cheaper than 61.76% of the companies in the same industry.
- AFX is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 24.26, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.5 | ||
| Fwd PE | 19.68 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AFX indicates a somewhat cheap valuation: AFX is cheaper than 77.94% of the companies listed in the same industry.
- AFX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. AFX is cheaper than 66.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.47 | ||
| EV/EBITDA | 11.55 |
4.3 Compensation for Growth
- AFX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- AFX's earnings are expected to grow with 22.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)1
PEG (5Y)7.47
EPS Next 2Y22.06%
EPS Next 3Y22.65%
5. Dividend
5.1 Amount
- AFX has a Yearly Dividend Yield of 1.39%.
- AFX's Dividend Yield is a higher than the industry average which is at 1.09.
- AFX's Dividend Yield is slightly below the S&P500 average, which is at 1.87.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.39% |
5.2 History
- The dividend of AFX decreases each year by -1.59%.
Dividend Growth(5Y)-1.59%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
- 37.19% of the earnings are spent on dividend by AFX. This is a low number and sustainable payout ratio.
DP37.19%
EPS Next 2Y22.06%
EPS Next 3Y22.65%
FRA:AFX (1/16/2026, 7:00:00 PM)
39.44
-0.22 (-0.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)12-11 2025-12-11/amc
Earnings (Next)02-10 2026-02-10
Inst Owners25.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.53B
Revenue(TTM)2.23B
Net Income(TTM)141.22M
Analysts71.82
Price Target49.78 (26.22%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.39% |
Yearly Dividend0.6
Dividend Growth(5Y)-1.59%
DP37.19%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.46%
Min EPS beat(2)-33.88%
Max EPS beat(2)-9.05%
EPS beat(4)1
Avg EPS beat(4)-16.59%
Min EPS beat(4)-36.67%
Max EPS beat(4)13.25%
EPS beat(8)4
Avg EPS beat(8)-3.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.89%
Min Revenue beat(2)-1.14%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-1.14%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.4%
PT rev (3m)-10.18%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.58%
EPS NY rev (3m)-6.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.64%
Revenue NY rev (3m)-0.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.5 | ||
| Fwd PE | 19.68 | ||
| P/S | 1.58 | ||
| P/FCF | 26.47 | ||
| P/OCF | 16.81 | ||
| P/B | 1.67 | ||
| P/tB | 7.29 | ||
| EV/EBITDA | 11.55 |
EPS(TTM)1.61
EY4.08%
EPS(NY)2
Fwd EY5.08%
FCF(TTM)1.49
FCFY3.78%
OCF(TTM)2.35
OCFY5.95%
SpS24.91
BVpS23.66
TBVpS5.41
PEG (NY)1
PEG (5Y)7.47
Graham Number29.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROCE | 7.81% | ||
| ROIC | 5.79% | ||
| ROICexc | 5.89% | ||
| ROICexgc | 14.08% | ||
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% | ||
| FCFM | 5.98% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
ROICexc(3y)7.22%
ROICexc(5y)9.75%
ROICexgc(3y)13.97%
ROICexgc(5y)15.82%
ROCE(3y)9.59%
ROCE(5y)13.04%
ROICexgc growth 3Y-8.4%
ROICexgc growth 5Y5.55%
ROICexc growth 3Y-23.03%
ROICexc growth 5Y-5.34%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
F-Score6
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Debt/EBITDA | 1.61 | ||
| Cap/Depr | 60.61% | ||
| Cap/Sales | 3.44% | ||
| Interest Coverage | 10.38 | ||
| Cash Conversion | 60% | ||
| Profit Quality | 94.37% | ||
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 3.42 |
F-Score6
WACC6.71%
ROIC/WACC0.86
Cap/Depr(3y)109.66%
Cap/Depr(5y)110.76%
Cap/Sales(3y)5.42%
Cap/Sales(5y)4.92%
Profit Quality(3y)64.92%
Profit Quality(5y)71.29%
High Growth Momentum
Growth
EPS 1Y (TTM)-19.9%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-14.49%
EPS Next Y24.48%
EPS Next 2Y22.06%
EPS Next 3Y22.65%
EPS Next 5Y19.64%
Revenue 1Y (TTM)7.82%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%8.27%
Revenue Next Year4.23%
Revenue Next 2Y5.18%
Revenue Next 3Y5.72%
Revenue Next 5Y6.21%
EBIT growth 1Y14.86%
EBIT growth 3Y-17.44%
EBIT growth 5Y4.69%
EBIT Next Year66.85%
EBIT Next 3Y28.21%
EBIT Next 5Y26.13%
FCF growth 1Y40.11%
FCF growth 3Y7.85%
FCF growth 5Y-0.04%
OCF growth 1Y-15.15%
OCF growth 3Y3.7%
OCF growth 5Y3.29%
CARL ZEISS MEDITEC AG - BR / AFX.DE FAQ
What is the fundamental rating for AFX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.
What is the valuation status of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?
CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 4 / 10.
What are the PE and PB ratios of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 24.5 and the Price/Book (PB) ratio is 1.67.
Is the dividend of CARL ZEISS MEDITEC AG - BR sustainable?
The dividend rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 3 / 10 and the dividend payout ratio is 37.19%.